The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Drug Repurposing for Rare Diseases
Open accessAbstract
Currently, there are about 7000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases. Although drug repurposing is not novel, new strategies have been developed in recent years to do it in a systematic and rational way. Here, we review applied methodologies, recent accomplished progress, and the challenges associated in drug repurposing for rare diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders
Yang, Y., Muzny, D. M., Reid, J. G., Bainbridge, M. N., Willis, A., Ward, P. A., Braxton, A., Beuten, J., Xia, F., Niu, Z., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306555 · Cited by 1,964
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database
Nguengang Wakap, S., Lambert, D. M., Olry, A., Rodwell, C., Gueydan, C., Lanneau, V., Murphy, D., Le Cam, Y., & Rath, A. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-019-0508-0 · Cited by 1,752
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Genetic diagnosis by whole exome capture and massively parallel DNA sequencing
Choi, M., Scholl, U. I., Ji, W., Liu, T., Tikhonova, I. R., Zumbo, P., Nayir, A., Bakkaloğlu, A., Özen, S., Sanjad, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910672106 · Cited by 1,329
Integrative omics for health and disease
Karczewski, K. J., & Snyder, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2018.4 · Cited by 1,158
Clinical Exome Sequencing for Genetic Identification of Rare Mendelian Disorders
Lee, H., Deignan, J. L., Dorrani, N., Strom, S. P., Kantarci, S., Quintero-Rivera, F., Das, K., Toy, T., Harry, B., Yourshaw, M., et al. (2014) · JAMA · doi:10.1001/jama.2014.14604 · Cited by 973
Blinding in randomised trials: hiding who got what
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07816-9 · Cited by 952
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Rare-disease genetics in the era of next-generation sequencing: discovery to translation
Boycott, K. M., Vanstone, M. R., Bulman, D. E., & MacKenzie, A. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3555 · Cited by 763
Can you teach old drugs new tricks?
Nosengo, N. (2016) · Nature · doi:10.1038/534314a · Cited by 729
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707305 · Cited by 703
Exploiting machine learning for end-to-end drug discovery and development
Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0338-z · Cited by 578
Hutchinson–Gilford progeria syndrome: Review of the phenotype
Hennekam, R. C. M. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31346 · Cited by 575
A survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555
The promise of whole-exome sequencing in medical genetics
Rabbani, B., Tekin, M., & Mahdieh, N. (2014) · Journal of Human Genetics · doi:10.1038/jhg.2013.114 · Cited by 542
Sessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I. D., Morena, F., Calabria, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30374-9 · Cited by 502
Human Genome Sequencing in Health and Disease
Gonzaga-Jauregui, C., Lupski, J. R., & Gibbs, R. A. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-051010-162644 · Cited by 473
Solomon, S. D., Adams, D., Kristen, A., Grogan, M., González-Duarte, A., Maurer, M. S., Merlini, G., Damy, T., Slama, M. S., Brannagan, T. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035831 · Cited by 462
Clinical application of exome sequencing in undiagnosed genetic conditions
Need, A. C., Shashi, V., Hitomi, Y., Schoch, K., Shianna, K. V., McDonald, M. T., Meisler, M. H., & Goldstein, D. B. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-100819 · Cited by 438
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 436
Drug repurposing from the perspective of pharmaceutical companies
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13798 · Cited by 429
Clinical research for rare disease: Opportunities, challenges, and solutions
Griggs, R. C., Batshaw, M., Dunkle, M., Gopal-Srivastava, R., Kaye, E., Krischer, J., Nguyen, T., Paulus, K., & Merkel, P. A. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.003 · Cited by 401
Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
Guengerich, F. P. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-062 · Cited by 387
Gordon, L. B., Kleinman, M. E., Miller, D. T., Neuberg, D. S., Giobbie-Hurder, A., Gerhard-Herman, M., Smoot, L. B., Gordon, C. M., Cleveland, R., Snyder, B. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202529109 · Cited by 375
In silico pharmacology for drug discovery: applications to targets and beyond
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707306 · Cited by 365
Unveiling the role of network and systems biology in drug discovery
Pujol, A., Mosca, R., Farrés, J., & Aloy, P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.006 · Cited by 346
The Prevalence of Huntington's Disease
Rawlins, M. D., Wexler, N. S., Wexler, A. R., Tabrizi, S. J., Douglas, I., Evans, S. J. W., & Smeeth, L. (2016) · Neuroepidemiology · doi:10.1159/000443738 · Cited by 331
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D., Bissell, D. M., Desnick, R., Parker, C., Phillips, J., Bonkovsky, H. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1807838 · Cited by 259
Systems approaches to polypharmacology and drug discovery.
Boran, A. D. W., & Iyengar, R. (2010) · PubMed · Cited by 257
Emerging therapies and challenges in spinal muscular atrophy
Farrar, M. A., Park, S. B., Vucic, S., Carey, K. A., Turner, B. J., Gillingwater, T. H., Swoboda, K. J., & Kiernan, M. C. (2017) · Annals of Neurology · doi:10.1002/ana.24864 · Cited by 247
Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome
Gordon, L. B., Massaro, J., D’Agostino, R. B., Campbell, S. E., Brazier, J., Brown, W. T., Kleinman, M. E., & Kieran, M. W. (2014) · Circulation · doi:10.1161/circulationaha.113.008285 · Cited by 244
Drug repositioning for orphan diseases
Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228
Empowerment of patients: lessons from the rare diseases community
Aymé, S., Kole, A., & Groft, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60875-2 · Cited by 227
Overcoming the legal and regulatory barriers to drug repurposing
Breckenridge, A., & Jacob, R. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.92 · Cited by 227
Clinical Trials in Rare Disease: Challenges and Opportunities
Augustine, E. F., Adams, H. R., & Mink, J. W. (2013) · Journal of Child Neurology · doi:10.1177/0883073813495959 · Cited by 222
Gordon, L. B., Shappell, H., Massaro, J., D’Agostino, R. B., Brazier, J., Campbell, S. E., Kleinman, M. E., & Kieran, M. W. (2018) · JAMA · doi:10.1001/jama.2018.3264 · Cited by 221
Boguski, M. S., Mandl, K. D., & Sukhatme, V. P. (2009) · Science · doi:10.1126/science.1169920 · Cited by 220
Xu, H., Aldrich, M. C., Chen, Q., Liu, H., Peterson, N. B., Dai, Q., Levy, M., Shah, A., Han, X., Ruan, X., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2014-002649 · Cited by 218
Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
O'Connor, K. A., & Roth, B. L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1900 · Cited by 215
The Emerging Paradigm of Network Medicine in the Study of Human Disease
Chan, S. Y., & Loscalzo, J. (2012) · Circulation Research · doi:10.1161/circresaha.111.258541 · Cited by 214
The known unknown: the challenges of genetic variants of uncertain significance in clinical practice
Hoffman-Andrews, L. (2017) · Journal of Law and the Biosciences · doi:10.1093/jlb/lsx038 · Cited by 214
Survey of healthcare experiences of Australian adults living with rare diseases
Molster, C., Urwin, D., Di Pietro, L., Fookes, M., Petrie, D., van der Laan, S., & Dawkins, H. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0409-z · Cited by 212
Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective
Dawkins, H. J. S., Draghia‐Akli, R., Lasko, P., Lau, L. P. L., Jonker, A. H., Cutillo, C. M., Rath, A., Boycott, K. M., Baynam, G., Lochmüller, H., et al. (2018) · Clinical and Translational Science · doi:10.1111/cts.12501 · Cited by 178
A Diagnosis for All Rare Genetic Diseases: The Horizon and the Next Frontiers
Boycott, K. M., Hartley, T., Biesecker, L. G., Gibbs, R. A., Innes, A. M., Riess, O., Belmont, J., Dunwoodie, S. L., Jojic, N., Lassmann, T., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.040 · Cited by 177
Finasteride: A Review of its Use in Male Pattern Hair Loss
McClellan, K. J., & Markham, A. (1999) · Drugs · doi:10.2165/00003495-199957010-00014 · Cited by 171
Health-related quality of life among adults with diverse rare disorders
Bogart, K. R., & Irvin, V. L. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0730-1 · Cited by 171
Kaufmann, P., Pariser, A., & Austin, C. P. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0936-x · Cited by 169
Genetic Modifiers and Rare Mendelian Disease
Rahit, K. M. T. H., & Tarailo-Graovac, M. (2020) · Genes · doi:10.3390/genes11030239 · Cited by 167
Soejima, H., & Higashimoto, K. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.51 · Cited by 161
Artificial intelligence (AI) in rare diseases: is the future brighter?
Brasil, S., Pascoal, C., Francisco, R., dos Reis Ferreira, V., A. Videira, P., & Valadão, G. (2019) · Genes · doi:10.3390/genes10120978 · Cited by 160
Liu, G., Zhu, H., Lagou, V., Gutin, B., Stallmann-Jorgensen, I. S., Treiber, F. A., Dong, Y., & Snieder, H. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-57 · Cited by 142
The major role of clinicians in the discovery of off-label drug therapies
DeMonaco, H. J., Ali, A., & von Hippel, E. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.323 · Cited by 142
Statistical Consideration of Adaptive Methods in Clinical Development
Chow, S., Chang, M., & Pong, A. (2005) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-200062277 · Cited by 136
Phase II Trials in Drug Development and Adaptive Trial Design
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.005 · Cited by 133
Blöß, S., Klemann, C., Rother, A.-K., Mehmecke, S., Schumacher, U., Mücke, U., Mücke, M., Stieber, C., Klawonn, F., Kortum, X., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172532 · Cited by 121
Genome sequencing and implications for rare disorders
Posey, J. E. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1127-0 · Cited by 121
Metz, J. T., & Hajduk, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.166 · Cited by 100
Cardiac abnormalities in patients with Hutchinson-Gilford progeria syndrome
Prakash, A., Gordon, L. B., Kleinman, M. E., Gurary, E. B., Massaro, J., D’Agostino, R., Kieran, M. W., Gerhard-Herman, M., & Smoot, L. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5235 · Cited by 98
Shameer, K., Readhead, B., & Dudley, J. T. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150112103510 · Cited by 95
Big data: the next frontier for innovation in therapeutics and healthcare
Issa, N. T., Byers, S. W., & Dakshanamurthy, S. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.905201 · Cited by 92
Induced pluripotent stem cells for neural drug discovery
Farkhondeh, A., Li, R., Gorshkov, K., Chen, K. G., Might, M., Rodems, S. M., Lo, D. C., & Zheng, W. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.007 · Cited by 91
Yu, D., Swaroop, M., Wang, M., Baxa, U., Yang, R., Yan, Y., Coksaygan, T., DeTolla, L. J., Marugán, J., Austin, C. P., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114537378 · Cited by 83
Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective
Ferreira, L. L. G., & Andricopulo, A. D. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.021 · Cited by 82
Verbaanderd, C., Rooman, I., Meheus, L., & Huys, I. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01664 · Cited by 82
Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens
Kuemmerle-Deschner, J. B., Wittkowski, H., Tyrrell, P. N., Koetter, I., Lohse, P., Ummenhofer, K., Reess, F., Hansmann, S., Koitschev, A., Deuter, C., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4237 · Cited by 75
Burgener, E. B., & Moss, R. B. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000627 · Cited by 75
Diagnosing rare diseases after the exomePreprint
Frésard, L., & Montgomery, S. B. (2018) · Molecular Case Studies · doi:10.1101/mcs.a003392 · Cited by 75
Cantú syndrome: Findings from 74 patients in the International Cantú Syndrome Registry
Grange, D. K., Roessler, H. I., McClenaghan, C., Duran, K. J., Shields, K., Remedi, M. S., Knoers, N. V. A. M., Lee, J., Kirk, E. P., Scurr, I. J., et al. (2019) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31753 · Cited by 72
Self-citationPivotal studies of orphan drugs approved for neurological diseases
Mitsumoto, J., Dorsey, E. R., Beck, C. A., Kieburtz, K. D., & Griggs, R. C. (2009) · Annals of Neurology · doi:10.1002/ana.21676 · Cited by 71
The patient’s view on rare disease trial design – a qualitative study
Gaasterland, C. M. W., der Weide, M. C. J., Olthof, M. J. D. P. –., Donk, M., Kaatee, M. M., Kaczmarek, R., Lavery, C., Leeson‐Beevers, K., O’Neill, N., Timmis, O. G., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1002-z · Cited by 71
Lenders, M., Nordbeck, P., Kurschat, C. E., Karabul, N., Kaufeld, J. K., Hennermann, J. B., Patten, M., Cybulla, M., Müntze, J., Üçeyler, N., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1832 · Cited by 71
Finding hidden treasures in old drugs: the challenges and importance of licensing generics
Simsek, M., Meijer, B., Bodegraven, A. A. V., de Boer, N. K. H., & Mulder, C. J. J. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.008 · Cited by 69
Hypertrichosis and Congenital Anomalies Associated With Maternal Use of Minoxidil
Kaler, S. G., Patrinos, M. E., Lambert, G. H., Myers, T. F., Karlman, R. L., & Anderson, C. L. (1987) · PEDIATRICS · doi:10.1542/peds.79.3.434 · Cited by 66
Murteira, S., Ghezaiel, Z., Karray, S., & Lamure, M. P. (2013) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v1i0.21131 · Cited by 65
Drug development for orphan diseases in the context of personalized medicine
Brewer, G. J. (2009) · Translational research · doi:10.1016/j.trsl.2009.03.008 · Cited by 57
Murteira, S., Millier, A., Ghezaiel, Z., & Lamure, M. P. (2014) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v2.22813 · Cited by 57
Rao, A., Saipradeep, V. G., Joseph, T., Kotte, S., Sivadasan, N., & Srinivasan, R. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0372-8 · Cited by 57
ksRepo: a generalized platform for computational drug repositioning
Brown, A. S., Kong, S. W., Kohane, I. S., & Patel, C. J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0931-y · Cited by 54
Advancing precision medicine with personalized drug screening
Gorshkov, K., Chen, C. Z., Marshall, R. E., Mihatov, N., Choi, Y., Nguyễn, Ð.-T., Southall, N. T., Chen, K. G., Park, J. K., & Zheng, W. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.010 · Cited by 52
Challenges in Whole Exome Sequencing: An Example from Hereditary Deafness
Sırmacı, A., Edwards, Y. J. K., Akay, H., & Tekin, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032000 · Cited by 50
Affordable orphan drugs: a role for not‐for‐profit organizations
Davies, E. H., Fulton, E., Brook, D., & Hughes, D. A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13240 · Cited by 48
Rare diseases in disabled children: an epidemiological survey
Guillem, P., Cans, C., Robert‐Gnansia, E., Aymé, S., & Jouk, P. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.104455 · Cited by 46
Pluripotent Stem Cell Platforms for Drug Discovery
Chen, K. G., Mallon, B. S., Park, K., Robey, P. G., McKay, R. D. G., Gottesman, M. M., & Zheng, W. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.009 · Cited by 43
Kinarivala, N., Patel, R., Boustany, R., Al-Ahmad, A. J., & Trippier, P. C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01199 · Cited by 40
Network medicine: linking disorders
Piro, R. M. (2012) · Human Genetics · doi:10.1007/s00439-012-1206-y · Cited by 36
From gene to treatment: supporting rare disease translational research through model systems
Hmeljak, J., & Justice, M. J. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039271 · Cited by 36
on behalf of the IRDiRC Data Mining and Repurposing Task Force, Southall, N. T., Natarajan, M., Lau, L. P. L., Jonker, A. H., Deprez, B. P., Guilliams, T., Hunter, L., Rademaker, C. M. A., Hivert, V., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1193-3 · Cited by 35
Saturation of the Human Phenome
Samuels, M. E. (2010) · Current Genomics · doi:10.2174/138920210793175886 · Cited by 32
Accelerating orphan drug development
Coté, T. R., Xu, K., & Pariser, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3340 · Cited by 31
A Computational Framework for Genome-wide Characterization of the Human Disease Landscape
Lee, Y.-S., Krishnan, A., Oughtred, R., Rust, J., Chang, C., Ryu, J., Kristensen, V. N., Dolinski, K. J., Theesfeld, C. L., & Troyanskaya, O. G. (2019) · Cell Systems · doi:10.1016/j.cels.2018.12.010 · Cited by 27
Rare Diseases: Drug Discovery and Informatics Resource
Zhao, M., & Wei, D. (2017) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-017-0270-3 · Cited by 26
An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening
Kinarivala, N., Morsy, A., Patel, R., Carmona, A. V., Sajib, M. S., Raut, S., Mikelis, C. M., Al-Ahmad, A. J., & Trippier, P. C. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00077 · Cited by 25
Hayes, A. G., & Nutt, D. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.510 · Cited by 13
Resources, challenges and way forward in rare mitochondrial diseases research
Rajput, N. K., Singh, V. K., & Bhardwaj, A. (2015) · F1000Research · doi:10.12688/f1000research.6208.1 · Cited by 9
Concept Modeling-based Drug Repositioning.
Patchala, J., & Jegga, A. G. (2015) · Europe PMC (PubMed Central) · Cited by 7
Mutation-specific therapies and drug repositioning in cystic fibrosis
Villella, V. R., Tosco, A., Esposito, S., Bona, G., Raia, V., & Maiuri, L. (2019) · Minerva Pediatrics · doi:10.23736/s0026-4946.19.05506-3 · Cited by 6
Syndrome-Associated Tumors by Organ System
Riddle, N. D., & González, R. S. (2016) · Journal of Pediatric Genetics · doi:10.1055/s-0036-1580597 · Cited by 3
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
AlphaFold, Artificial Intelligence (AI), and Allostery
Nussinov, R., Zhang, M., Liu, Y., & Jang, H. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c04346 · Cited by 190
Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064732 · Cited by 168
“This is a timesaving, cost-efficient method that can accelerate the development of RDs treatments [59].”
MethodToward responsible clinical n-of-1 strategies for rare diseases
Defelippe, V. M., J.M.W. van Thiel, G., Otte, W. M., Schutgens, R. E. G., Stunnenberg, B., Cross, H. J., O'Callaghan, F., De Giorgis, V., Jansen, F. E., Perucca, E., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103688 · Cited by 30
Metadata
- Authors
- Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 42
- Issue
- 4
- Pages
- 255-267
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W3127311830
- Cited by
- 269
- References
- 104
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.